Cost-Effectiveness Analysis Among Patients With Diabetes Mellitus or Cardiovascular Disease Receiving Second-Line Treatment With Intensive Doses of Simvastatin Atorvastatin and Atorvastatin-Ezetimibe Combination In General Practice

Line Treatment ◽

Second Line ◽

Effectiveness Analysis ◽

Patients With Diabetes

Cost-Effectiveness Analysis Of Simvastatin Atorvastatin And Atorvastatin-Ezetimibe Combination Among Patients With Diabetes Mellitus Or Cardiovascular Disease In General Practice

Value in Health ◽

10.1016/j.jval.2015.03.820 ◽

2015 ◽

Vol 18 (3) ◽

pp. A141

Author(s):

H. Rattanakunooprakarn ◽

K. Tewthanom ◽

P. Sakthong

Keyword(s):

Diabetes Mellitus ◽

Cardiovascular Disease ◽

General Practice ◽

Cost Effectiveness ◽

Effectiveness Analysis ◽

Patients With Diabetes

PDB7 Cost-Effectiveness Analysis of Once-Weekly Semaglutide As the Second-LINE Treatment for Type 2 Diabetes Mellitus Patients

Value in Health Regional Issues ◽

10.1016/j.vhri.2020.07.166 ◽

2020 ◽

Vol 22 ◽

pp. S33

Author(s):

M.C. Yang ◽

E.C.H. Tan

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Cost Effectiveness ◽

Line Treatment ◽

Second Line ◽

PSY100 - COST-EFFECTIVENESS ANALYSIS OF SECOND LINE TREATMENT FOR PATIENTS WITH ULCERATIVE COLITIS

Value in Health ◽

10.1016/j.jval.2018.09.2675 ◽

2018 ◽

Vol 21 ◽

pp. S453

Author(s):

C. De La Puente ◽

V. Hurtado

Keyword(s):

Ulcerative Colitis ◽

Cost Effectiveness ◽

Line Treatment ◽

Second Line ◽

Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients

Clinical Rheumatology ◽

10.1007/s10067-019-04739-3 ◽

2019 ◽

Vol 38 (12) ◽

pp. 3521-3528 ◽

Cited By ~ 1

Author(s):

María Presa ◽

Fernando Pérez-Ruiz ◽

Itziar Oyagüez

Keyword(s):

Cost Effectiveness ◽

Line Treatment ◽

Second Line ◽

Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population

BMC Cancer ◽

10.1186/1471-2407-10-26 ◽

2010 ◽

Vol 10 (1) ◽

Cited By ~ 19

Author(s):

Yumi Asukai ◽

Amparo Valladares ◽

Carlos Camps ◽

Eifiona Wood ◽

Kaisa Taipale ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

CN1 A COST—EFFECTIVENESS ANALYSIS MODEL FOR THE SECOND LINE TREATMENT OF GASTROINTESTINAL STROMAL TUMOURS (GIST) IN MEXICO

Value in Health ◽

10.1016/s1098-3015(10)68566-x ◽

2007 ◽

Vol 10 (3) ◽

pp. A11 ◽

Cited By ~ 1

Author(s):

I Contreras-Hernandez ◽

J Mould-Quevedo ◽

G Salinas-Escudero ◽

A Silva ◽

J Tapia-Valencia ◽

...

Keyword(s):

Cost Effectiveness ◽

Line Treatment ◽

Second Line ◽

Analysis Model ◽

Gastrointestinal Stromal Tumours ◽

Cost-effectiveness analysis of camrelizumab in the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China

Annals of Translational Medicine ◽

10.21037/atm-21-1803 ◽

2021 ◽

Vol 0 (0) ◽

pp. 0-0

Author(s):

Fan Yang ◽

Yu Fu ◽

Arun Kumar ◽

Mingsheng Chen ◽

Lei Si ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cost Effectiveness ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Line Treatment ◽

Second Line ◽

Cost-Effectiveness Analysis of Nilotinib Versus High-Dose Imatinib for the Second-Line Treatment of Chronic Myeloid Leukemia In China : Based on Nation-Wide Data

Value in Health ◽

10.1016/j.jval.2018.04.1712 ◽

2018 ◽

Vol 21 ◽

pp. S254

Author(s):

L Guan ◽

C Huang ◽

Y Liu

Keyword(s):

Cost Effectiveness ◽

Chronic Myeloid Leukemia ◽

Myeloid Leukemia ◽

High Dose ◽

Line Treatment ◽

Second Line ◽

PCN23 COST-EFFECTIVENESS ANALYSIS OF LAPATINIB PLUS CAPECITABINE VERSUS CAPECITABINE ALONE IN THE SECOND LINE TREATMENT FOR BREAST CANCER TREATMENT

Value in Health ◽

10.1016/s1098-3015(10)70201-1 ◽

2008 ◽

Vol 11 (3) ◽

pp. A60-A61 ◽

Cited By ~ 1

Author(s):

F Ejzykowicz ◽

JW Hay

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Cancer Treatment ◽

Breast Cancer Treatment ◽

Line Treatment ◽

Second Line ◽

Initial therapy with empagliflozin in addition to metformin vs standard therapy alone for patients with type 2 diabetes mellitus and cardiovascular disease in qatar. A cost-effectiveness analysis

Endocrine Abstracts ◽

10.1530/endoabs.73.aep33 ◽

2021 ◽

Author(s):

Dina Abushanab ◽

Daoud Al-Badriyeh ◽

Danny Liew ◽

Zanfina Ademi

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Cardiovascular Disease ◽

Type 2 Diabetes Mellitus ◽

Cost Effectiveness ◽

Standard Therapy ◽

Initial Therapy ◽